You just read:

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

News provided by

Amgen

Dec 11, 2014, 04:01 ET